Riskpilot← Back to searchSign inGet full accessRMF INVEST AS
ASActiveOrg 988976180Taubaneveien 52, 4825 ArendalRetail sale of pharmaceutical products · NACE 4773Est. 20060 employees
Revenue 2025
NOK 142K
EBITDA margin
16.6%
+159% vs 2024
Equity ratio
82.4%
Financial strength
Net profit 2025
NOK 17,8M
+637% vs 2024
| Revenue | NOK 142K | — |
| EBITDA | NOK 24K | +159% |
| Net profit | NOK 17,8M | +637% |
| Total assets | NOK 15,6M | +12% |
| Equity | NOK 12,8M | +6% |
| Employees | 0 | — |
Legal name
RMF INVEST AS
Org number
988976180
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
25. januar 2006
Share capital
NOK 255 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Tilby farmasøytiske tjenester til apotek, samt å eie aksjer i andre selskaper, eie og investere i fast eiendom og annen investeringsvirksomhet.
Address
Taubaneveien 52, 4825 Arendal
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 142 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −25 | −29 | −32 | −40 | 24 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −25 | −29 | −32 | −40 | 24 |
| Net financials | 1 034 | 1 221 | 2 289 | 2 532 | 17 879 |
| Profit before tax | 1 009 | 1 193 | 2 257 | 2 492 | 17 903 |
| Tax | 2 | −0 | 43 | 81 | 135 |
| Net profit | 1 007 | 1 193 | 2 214 | 2 410 | 17 768 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 11 655 | 11 336 | 12 616 | 13 893 | 15 579 |
| Equity | 10 698 | 10 359 | 11 381 | 12 069 | 12 833 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 957 | 977 | 1 235 | 1 824 | 2 746 |
| Total debt | 957 | 977 | 1 235 | 1 824 | 2 746 |
EBITDA margin
16.6%
This company
15.8%
Market median
+5% vs market
20212025
Equity ratio
82.4%
This company
38.2%
Market median
+116% vs market
20212025
Return on equity
138.4%
This company
18.4%
Market median
+652% vs market
20212025
Net profit margin
12477.2%
This company
8.1%
Market median
+153940% vs market
20212025
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20212025
Debt / equity
0.21×
This company
0.62×
Market median
+66% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
RM Chief Executive Officer | Chief Executive Officer | 2025 |
LT Chief Executive Officer | Chief Executive Officer | 2006 |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
RMF INVEST AS 
APOTEK 1 BJORBEKK ASBoard members of RMF INVEST AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ragnar Madsen | Chief Executive Officer | 0 companies |
| Lloyd Thygesen | Chief Executive Officer | 0 companies |